A
6.53
-0.21 (-3.05%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Aura Biosciences, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
-0.8
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.83 |
|
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 1.98% |
| 机构持股比例 | 76.19% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Matrix Capital Management Company, Lp | 31 Mar 2026 | 6,922,870 |
| Caligan Partners Lp | 30 Jun 2026 | 4,298,248 |
| Fcpm Iii Services B.V. | 30 Jun 2026 | 4,053,775 |
| Medicxi Ventures Management (Jersey) Ltd | 30 Jun 2026 | 3,039,892 |
| Nantahala Capital Management, Llc | 30 Jun 2026 | 2,951,030 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合